Group
photo
of
the
launch
of
肌顏態®
The
Group’s
strategic
cooperation
product
with
Chongqing
Minji
Medical
Device
Co.,
Ltd.,
recombinant
collagen
dressing,
has
successfully
received
Class
II
medical
device
approval,
with
the
approval
number
“渝械注准
20242140377”.
At
the
same
time,
the
Group’s
self-developed
medical
aesthetics
product,
肌顏態®,
was
successfully
launched,
marked
by
a
grand
event
held
in
Wuhan.
The
launch
brought
together
industry
experts,
key
opinion
leaders,
media
representatives,
and
other
professionals
to
witness
the
Group’s
entry
into
the
rapidly
growing
medical
aesthetics
market,
valued
at
hundreds
of
billions
of
RMB.
This
milestone
signifies
a
bold
new
chapter
for
the
Group
as
it
continues
to
expand
its
presence
in
this
high-potential
sector.
Collagen, which is central to the newly approved recombinant collagen dressing, is the most abundant protein in the human body, comprising 25–35% of total protein content. It forms a network of elastic fibers that support the skin’s structure, maintain elasticity, and lock in moisture. However, collagen production decreases by approximately 1% annually after maturity (around age 21), leading to a loss of skin firmness and elasticity. Collagen-based products have a wide range of applications, including moisturizing, maintaining the skin barrier, and addressing signs of aging. In addition to dressing, microneedles for collagen are also being developed.
The launch of 肌顏態®, developed based on proprietary patents of Skbrella™ FN (Recombinant Human Fibronectin), marks another key milestone in the Group’s efforts to expand its portfolio. 肌顏態® is designed to provide safe, effective solutions for improving skin quality and repair, making it ideal for treating damaged skin, acne-prone skin, and for post-medical procedure care. Fibronectin, a multifunctional extracellular matrix glycoprotein, plays a vital role in cell migration, adhesion, proliferation, hemostasis, and tissue repair. It is worth mentioning that the Group is advancing the development of its fibronectin-based medical device.
Photo
left:肌顏態®
Fibronectin
Repair
Solution;
Photo
right:肌顏態®
Fibronectin
Serum
The
debut
of肌顏態®
has
attracted
high
recognition
and
attention
from
many
dermatologists
and
medical
aesthetics
practitioners.
At
the
launch,
experts
and
scholars
conducted
professional
academic
exchanges
and
case
sharing
on
the
effects
and
clinical
use
of
fibronectin
from
different
perspectives
“肌顏態®,
a
product
designed
for
use
throughout
the
entire
cycle
of
preoperative
and
post-medical
procedures,
demonstrates
significant
effectiveness,
particularly
for
patients
with
anesthetic
allergies.
It
enables
rapid
skin
repair
and
reduces
redness
efficiently.”
Dermatology
clinical
practice
sharing
by
Professor
Yang
Bin,
President
of
Guangdong
Dermatology
Hospital,
Southern
Medical
University
肌顏態®
use
case
sharing
by
Professor
Shi
Ge,
Director
of
the
Department
of
Plastic
Surgery
of
the
Sixth
Affiliated
Hospital
of
Sun
Yat-sen
University
Mr.
Frank
Zhao,
CEO
of
Uni-Bio
Science
Group,
also
said:
“The
Group
will
leverage
its
professional
expertise
in
dermatology,
nearly
three
decades
robust
clinical
data
from
GeneTime
,
and
its
established
sales
network,
adhering
to
the
rigorous
R&D
standards
of
pharmaceutical
companies,
to
build
a
diversified
product
portfolio
across
biological
drugs,
medical
devices,
and
medical
aesthetics,
ultimately
providing
safer
and
more
effective
full-cycle
skincare
solutions
for
patients.”
Photo
left:
Mr.
Frank
Zhao,
CEO
of
Uni-Bio
Science
Group
delivered
opening
speech
for
the
launch
of
肌顏態®;
Photo
right:
Dr.
Yu
Shan,
Deputy
Director
of
R&D
and
Project
of
Uni-Bio
Science
Group,
introduction
of
肌顏態®
The
Group
is
well-positioned
to
capitalize
on
the
growing
opportunities
in
the
market.
Industry
forecasts
indicate
that
the
medical
aesthetic
market
is
set
to
sustain
a
CAGR
growth
of
10%
to
15%
between
2024
and
2027,
and
is
expected
to
exceed
RMB
600
billion
in
2030.
The
approval
of
collagen
medical
devices
and
the
launch
of
肌顏態®
herald
a
new
journey
for
the
Group
in
the
field
of
skin
care.
Mr.
Kingsley
Leung,
Chairman
of
Uni-Bio
Science
Group,
success
entered
in
partnerships
with
various
renowned
medical
aesthetics
clinic
chain
and
distributors
These
achievements
reflect
the
Group’s
strong
commitment
to
innovation,
strategic
execution,
and
value
creation.
As
the
Group
continues
to
execute
its
strategic
vision,
it
remains
focused
on
its
goal
of
becoming
China’s
leading
expert
in
dermatology,
leveraging
innovation,
clinical
expertise,
and
market
insight
to
drive
sustainable
growth
and
long-term
success.
Hashtag: #Uni-BioScience
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate